Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. European Lung Cancer Congress 2025

Above RECIST: A new role for MRD and cfDNA in tumour assessment

Is liquid biopsy a tool for detecting early relapse in lung cancer patients?

Date

27 Mar 2025

Session

Above RECIST: A new role for MRD and cfDNA in tumour assessment

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Heather Wakelee

Authors

H. Wakelee

Author affiliations

  • Standford University, Stanford/US

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Q&A and discussion

Session: Above RECIST: A new role for MRD and cfDNA in tumour assessment

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.